



UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION I
475 ALLENDALE ROAD
KING OF PRUSSIA, PENNSYLVANIA 19406-1415

January 6, 2005

Docket No. 03002535
Control No. 135851

License No. 29-11642-01

Albert L. Gutierrez
President
Shore Memorial Hospital
1 East New York Avenue
Somers Point, NJ 08244-2387

SUBJECT: SHORE MEMORIAL HOSPITAL, ISSUANCE OF LICENSE AMENDMENT,
CONTROL NO. 135851

Dear Mr. Gutierrez:

This refers to your license amendment request. Enclosed with this letter is the amended license removing four authorized users, modifying the authorized use for two individuals to include studies or procedures permitted by 10 CFR 35.300, and increasing your possession limit to 300 millicuries for byproduct material permitted by 10 CFR 35.300.

Please review the enclosed document carefully and be sure that you understand and fully implement all the conditions incorporated into the amended license. If there are any errors or questions, please notify the U.S. Nuclear Regulatory Commission, Region I Office, Licensing Assistance Team, (610) 337-5239, so that we can provide appropriate corrections and answers.

An environmental assessment for this action is not required, since this action is categorically excluded under 10 CFR 51.22(c)(14).

Please note that on October 25, 2004, the NRC suspended public access to ADAMS, and initiated an additional security review of publicly available documents to ensure that potentially sensitive information is removed from the ADAMS database accessible through the NRC's web site. Interested members of the public may obtain copies of the referenced documents for review and/or copying by contacting the NRC Public Document Room pending resumption of public access to ADAMS. The NRC Public Document Room is located at NRC Headquarters in Rockville, MD, and can be contacted at 800-397-4209 or 301-415-4737 or pdr@nrc.gov.

A. Gutierrez
Shore Memorial Hospital

2

Thank you for your cooperation.

Sincerely,

Original signed by Pamela J. Henderson

Pamela J. Henderson
Chief
Medical Branch
Division of Nuclear Materials Safety

Enclosure:
Amendment No. 37

cc:
Jonathan N. Law, Radiation Safety Officer

DOCUMENT NAME: E:\Filenet\ML050120476.wpd

To receive a copy of this document, indicate in the box: "C" = Copy w/o attach/encl "E" = Copy w/ attach/encl "N" = No copy

OFFICE	DNMS/RI	N	DNMS/RI	N	DNMS/RI			
NAME	JNick /JLN/		PHenderson /PJH/					
DATE	1/6/05		1/6/05					

OFFICIAL RECORD COPY

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Shore Memorial Hospital</p> <p>2. 1 East New York Avenue Somers Point, New Jersey 08244</p>	<p>In accordance with the letter dated October 14, 2004,</p> <p>3. License number 29-11642-01 is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration date June 30, 2011</p> <hr/> <p>5. Docket No. 030-02535 Reference No.</p>
---	---

<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Iodine-125</p> <p>E. Any byproduct material permitted by 10 CFR 31.11</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Sealed Sources</p> <p>F. Prepackaged Kits</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. 300 millicuries</p> <p>D. 300 millicuries</p> <p>F. 5 millicuries</p>
--	---	---

<p>9. Authorized use:</p> <p>A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.</p> <p>B. Any imaging and localization study permitted by 10 CFR 35.200.</p> <p>C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300 for which the patient can be released according to the provisions of 10 CFR 35.75.</p> <p>D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.</p> <p>E. <u>In vitro</u> studies</p>
--

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
29-11642-01

Docket or Reference Number
030-02535

Amendment No. 37

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located at 1 East New York Avenue, Somers Point, New Jersey.
11. The Radiation Safety Officer for this license is Jonathan N. Law, M.S.
12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for the materials and uses indicated:

Authorized Users

Material and Use

Richard O'Laughlin, M.D.

35.100; 35.200; In vitro studies

Louis Gualtieri, D.O.

35.100; 35.200; In vitro studies

James W. Ziccardi, D.O.

35.200 for cardiovascular clinical procedures

Rich Menghetti, M.D.

35.100; 35.200
Iodine 131 for the treatment of hyperthyroidism and cardiac dysfunction

Jorge Cassir, M.D.

35.300
Iodine 131 for treatment of hyperthyroidism and cardiac dysfunction
Iodine 125 for uses identified in 10 CFR 35.400

James Wurzer, M.D.

35.300; 35.400

Jeffrey Meltzer, M.D.

35.300
Iodine 131 for treatment of hyperthyroidism and cardiac dysfunction
Iodine 125 for uses identified in 10 CFR 35.400

Robert Cifers, M.D.

35.100; 35.200; 35.300 except thyroid carcinoma

David Begleiter, M.D.

35.100; 35.200

Harry Allen Cooperman, M.D.

35.100; 35.200

Francesco G. Florio, D.O.

35.100; 35.200


**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
29-11642-01

Docket or Reference Number
030-02535

Amendment No. 37

- 13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
- 14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
- 15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
 - A. Letter dated February 20, 2001 (ML011560392)



For the U.S. Nuclear Regulatory Commission

Original signed by Pamela J. Henderson

Date January 6, 2005
bbbbbbbbbbbbbbbbbbbbbbbbbb

By _____
Pamela J. Henderson, Chief
Medical Branch
Division of Nuclear Materials Safety
Region I
King of Prussia, Pennsylvania 19406